Atentiv

About Atentiv

Atentiv develops digital therapeutics designed to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children. The company was founded in 2009 by Eric B. Gordon, who was motivated by his own children's experiences with ADHD. Gordon, a veteran entrepreneur in medical technologies, licensed initial technology from Duke University and conducted the first funded study in 2012.

The core of Atentiv's offering is a digital treatment platform, ATENTIVmynd™, which features game-based therapies like 'Skylar's Run' to improve attention and impulse control. This system utilizes a proprietary electroencephalography (EEG) headband that provides real-time neurofeedback, allowing the game's difficulty to adapt to the user's attention levels. As a child focuses, their in-game avatar performs better, effectively training the brain's attention circuits through neuroplasticity. The product is designed for home use and targets cognitive skills such as focused, sustained, and selective attention.

The company's business model focuses on providing these digital learning tools to consumers, educators, and clinicians. Atentiv operates as Atentiv Health and has a subsidiary, Attention Therapeutics, LLC, which focuses on products for medical professionals. While its main product, 'Skylar's Run', has undergone multiple clinical trials showing significant symptom reduction, it is not yet FDA-cleared. The company has secured funding through various rounds, including an $8 million financing round in 2013 and a $3 million loan in 2016 to advance commercialization and manufacturing. However, according to PitchBook, the company was marked as 'Out of Business' as of late 2023.